Global Blood Therapeutics Inc (GBT) Shares Bought by BlackRock Inc.

BlackRock Inc. lifted its position in Global Blood Therapeutics Inc (NASDAQ:GBT) by 27.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,142,762 shares of the company’s stock after acquiring an additional 898,162 shares during the period. BlackRock Inc. owned 7.96% of Global Blood Therapeutics worth $187,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. State of Wisconsin Investment Board boosted its stake in shares of Global Blood Therapeutics by 40.6% in the second quarter. State of Wisconsin Investment Board now owns 52,300 shares of the company’s stock worth $2,364,000 after acquiring an additional 15,100 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Global Blood Therapeutics by 19.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 23,669 shares of the company’s stock worth $1,070,000 after acquiring an additional 3,900 shares during the last quarter. Swiss National Bank boosted its stake in shares of Global Blood Therapeutics by 3.9% in the first quarter. Swiss National Bank now owns 76,600 shares of the company’s stock worth $3,700,000 after acquiring an additional 2,900 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Global Blood Therapeutics by 195.0% in the first quarter. Royal Bank of Canada now owns 175,113 shares of the company’s stock worth $8,458,000 after acquiring an additional 115,746 shares during the last quarter. Finally, American Century Companies Inc. acquired a new stake in shares of Global Blood Therapeutics in the second quarter worth approximately $2,680,000. 98.79% of the stock is currently owned by hedge funds and other institutional investors.

In other Global Blood Therapeutics news, insider Lesley Ann Calhoun sold 2,004 shares of Global Blood Therapeutics stock in a transaction on Friday, August 17th. The stock was sold at an average price of $49.89, for a total value of $99,979.56. Following the sale, the insider now owns 1,342 shares in the company, valued at $66,952.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Deval L. Patrick sold 42,379 shares of Global Blood Therapeutics stock in a transaction on Friday, July 6th. The shares were sold at an average price of $43.40, for a total value of $1,839,248.60. Following the completion of the sale, the director now owns 15,000 shares in the company, valued at approximately $651,000. The disclosure for this sale can be found here. Insiders sold 48,678 shares of company stock worth $2,128,844 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Shares of Global Blood Therapeutics stock opened at $40.70 on Wednesday. Global Blood Therapeutics Inc has a one year low of $27.55 and a one year high of $68.05. The company has a market cap of $2.07 billion, a P/E ratio of -14.75 and a beta of 4.26.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Thursday, August 2nd. The company reported ($0.78) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.09. During the same period in the previous year, the company posted ($0.55) EPS. analysts forecast that Global Blood Therapeutics Inc will post -3.38 EPS for the current year.

A number of equities analysts recently commented on GBT shares. Wedbush reiterated an “outperform” rating and set a $70.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, June 18th. Cantor Fitzgerald lifted their price objective on Global Blood Therapeutics from $69.00 to $96.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 27th. Wells Fargo & Co lifted their price objective on Global Blood Therapeutics from $78.00 to $85.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 27th. HC Wainwright lifted their price objective on Global Blood Therapeutics from $73.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, June 27th. Finally, Nomura lifted their price objective on Global Blood Therapeutics from $91.00 to $109.00 and gave the stock a “buy” rating in a research report on Thursday, June 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Global Blood Therapeutics presently has an average rating of “Buy” and an average price target of $80.53.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

See Also: Outstanding Shares

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply